Samsung Bioepis begins phase 3 clinical study for its Keytruda biosimilar
The Korea Herald - 2024-04-05T07:19:18.000Z

Samsung Bioepis, Samsung Group’s biosimilar arm, announced Friday that the company had started a phase 3 clinical study for SB27, a Keytruda biosimilar. Keytruda is an immuno-oncology drug developed by MSD, a US multinational pharmaceutical company. Indications for the drug include non-small cell lung cancer (NSCLC), melanoma and neck cancer. According to MSD's earnings release, global sales of Keytruda in

In related news

Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)
INCHEON, Korea, April 05, 2024 (GLOBE NEWSWIRE) — Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the company's proposed biosimilar referencing Keytrudai (pembrolizumab). The Phase 3 clinical trial for SB27 is a randomized, double-blind, parallel group
- Related Articles
- In News
- From www.tradingview.com
- 2024-04-05T05:00:41.000Z
Samsung Biopeis’ Keytruda biosimilar enters Phase III trials
Samsung Biopeis has initiated a Phase III trial for its proposed Keytruda (pembrolizumab) biosimilar referenced candidate SB27. The...
- Related Articles
- In News
- From Clinical Trials Arena
- 2024-04-05T14:03:25.000Z
Samsung Bioepis Kicks Off Phase III Pembrolizumab Trial
Samsung Bioepis has begun Phase III trials for its SB27 proposed pembrolizumab biosimilar to Keytruda – although the firm is just one of many developers eyeing the opportunity.
- Related Articles
- In News
- From Generics Bulletin
- 2024-04-05T10:30:08.000Z

In related news

Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)

Samsung Biopeis’ Keytruda biosimilar enters Phase III trials

Samsung Bioepis Kicks Off Phase III Pembrolizumab Trial